Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

A Pharmacological Advantage of Ursodeoxycholic Acid in Cytoprotection in Primary Rat Microglia

  • Joo, Seong-Soo (Department of Immunology, College of Pharmacy, Chung-Ang University) ;
  • Hwang, Kwang-Woo (Department of Immunology, College of Pharmacy, Chung-Ang University) ;
  • Lee, Do-Ik (Department of Immunology, College of Pharmacy, Chung-Ang University)
  • Published : 2005.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Ursodeoxycholic acid (UDCA) has long been used as an adjuvant or first choice of therapy for liver disease. Commonly, UDCA has been reported to play a role in improving hyperbilirubinemia and disorder of bromsulphalein. More commonly, UDCA has been used in reducing the rate of cholesterol level in bile juice that can cause cholesterol stone. The effects on the promotion of bile acid release that leads an excretion of toxic materials and wastes produced in liver cells as well as various arrays of liver disease such as hepatitis. Other than already reported in clinical use, immunosuppressive effect has been studied, especially in transplantation. In the study, we hypothesized that UDCA might have a certain role in anti-inflammation through a preventive effect of pro-inflammatory potentials in the brain macrophages, microglia. We found that the treatment of $200\;{\mu}g/ml$ UDCA effectively suppressed the pro-inflammatory mediators (i.e. nitric oxide and interleukin-$1{\beta}$) in rat microglia compared to comparators. Interestingly, RT-PCR analysis suggested that UDCA strongly attenuated the expression of $IL-1{\beta}$ that was comparable with cyclosporine A at 48 h incubation. Conclusively, we found that UDCA may playa cytoprotective role in microglial cells through direct or indirect pathways by scavenging a toxic compound or an anti-inflammatory effect, which are known as major causes of neurodegenerative diseases.

Keywords

References

  1. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron. 6, 487-498 (1991) https://doi.org/10.1016/0896-6273(91)90052-2
  2. Dickson, D.W., Lee, S.C., Mattiace, L.A., Yen, S.H. & Brosnan, C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7, 75-83 (1993) https://doi.org/10.1002/glia.440070113
  3. Lue, L.F. & Walker, D.G. Modeling Alzheimer's disease immune therapy mechanisms; interaction of human postmortem microglia with antibody- opsonized amyloid beta peptide. J. Neurosci Res. 70, 599- 610 (2002) https://doi.org/10.1002/jnr.10422
  4. Bayer, T.A., Wirths, O., Majtenyl, K., Hartmann, T., Multhaup, G., Beyreuther, K. & Czech, C. Key factors in Alzheimer's disease: ${\beta}-amyloid$ precursor protein processing, metabolism, and intraneuronal transport. Brain Pathology 11, 1-11 (2001)
  5. Giulian, D., Baker, T.J., Shih, L. & Lachman, L.B. Interleukin-1 of the central nervous system is produced by ameboid microglia. J. Exp Med 164, 594-604 (1986) https://doi.org/10.1084/jem.164.2.594
  6. Giulian, D. Ameboid microglia as effectors of inflammation in the central nervous system. J. Neuroscience Res. 18, 155-171 (1987) https://doi.org/10.1002/jnr.490180123
  7. Banati, R.B., Gehrmann, J., Schubert, P. & Kreutzberg, G.W. Cytotoxicity of microglia. Glia 7, 111- 118 (1996) https://doi.org/10.1002/glia.440070117
  8. Rodrigues, C.M.P., Ma, X., Kren, B.T. & Streer, C.J. A novel role for ursodeoxycholic acid in inhibiting apotosis by modulating mitochondrial membrane perturbation. J. Clin Invest 101, 2790-2799 (1998) https://doi.org/10.1172/JCI1325
  9. Kim, S.H., Won, S.J., Sohn, S.H., Kwon, H.J., Lee, J.Y., Park, J.H. & Gwag, B.J. Brain-derived neurotrophic factor can act as a pronecrotic factor through transcriptional and translocational activation of NADPH oxidase. J. Cell Biol 159, 821-831 (2002) https://doi.org/10.1083/jcb.200112131
  10. Yanker, B.A., Duffy, L.K. & Kirschner, D.A. Neuroprophic and neurotoxic effects of amyloid ${\beta}$ protein: Reversal by tachykinin neuropeptide. Science 250, 279-282 (1990). https://doi.org/10.1126/science.2218531
  11. Chao, C.C., Hu, S., Molitor, T.W., Shaskan, E.C. & Peterson, P.K. Activated microglia mediated neuronal cell injury via a nitric oxide mechanism. J. Immunol 149, 2736-2741 (1992)
  12. Chung, H., Brazil, M., Soe, T.T. & Maxfield, F.R. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J. Biol Chem 274, 32301-32308 (1999) https://doi.org/10.1074/jbc.274.45.32301
  13. Possel, H., Noack, H., Putzke, J., Wolf, G. & Sies, H. Selective upregulation of inducible Nitric Oxide Synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia. Glia 32, 51-59 (2000) https://doi.org/10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4
  14. Kim, W.G., Mohney, R.P., Wilson, B., Heohn, G.H., Liu, B. & Hong, J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J. Neurosci 20, 6309- 6316 (2000)
  15. Meda, L., Cassatella, M.A., Szendrei, G.I., Baron, P., Villalba, M., Ferrari, D. & Rossi, F. Activation of microglia cell by ${\beta}-amyloid$ protein and interferon-${\alpha}$. Nature 374, 647-650 (1995) https://doi.org/10.1038/374647a0
  16. Benveniste, E.N. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am. J. Physiol. 263, 1-16 (1992) https://doi.org/10.1152/ajpcell.1992.263.3.1-a
  17. Strijbos, P.J. & Rothwell, N.J. Interleukin-1beta attenuates excitatory aminoacid-induced neurodegenerstion in vitro: involvement of nerve growth factor. J. Neurosci 153, 3468-3474 (1995)
  18. Lue, L. et al. J. Inflammatory repertories of Alzheimer's disease and non demented elderly microglia in vitro. Glia 35, 72-79. (2001) https://doi.org/10.1002/glia.1072
  19. Forloni, G., Demichelli, F., Giorgi, S., Bendotti, C. & Angeretti, N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal, and glial cell: modulation by interleukin-1. Brain Res. 16, 128-134 (1992) https://doi.org/10.1016/0169-328X(92)90202-M
  20. Mrak, R.E., Sheng, J.G. & Griffin, W.S.T. Glial cytokines in Alzheimer's disease: reveiwand pathogenic implication. Hum Pathol 26, 816-823. (1995) https://doi.org/10.1016/0046-8177(95)90001-2
  21. Sheng, J.G., Ito, K., Skinner, R.D., Mrak, C.R., Van Eldik, L.J. & Griffin, W.S.T. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 17, 761-766 (1996) https://doi.org/10.1016/0197-4580(96)00104-2
  22. Jaffrey, S.R. & Snyder, S.H. Nitric oxide: a neural me-ssenger. Annu Rev Cell Dev 11, 417-440 (1995)
  23. Varadarajan, S., Yatin, S., Aksenova, M. & Butterfield, D.A. Alzheimer's amyloid beta-peptide associated free radical oxidative stress and neurotoxicity. J. Structural Biol 130, 184-208 (2000) https://doi.org/10.1006/jsbi.2000.4274
  24. Joo, S.S., Won, T.J. & Lee, D.I. Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch Pharm Res. 27, 954-960 (2004) https://doi.org/10.1007/BF02975850
  25. Bowie, A. & O'Neill, L.A.J. Oxidative stress and nuclear Factor-${\kappa}B$ activation; a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59, 13-23 (2000) https://doi.org/10.1016/S0006-2952(99)00296-8